Holger Rosenbrock

Neuroscience & Mental Health DR
Biberach An Der Riss, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia.

The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia.

Journal: Journal of clinical pharmacology

Published: October 30, 2025

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

Journal: Clinical pharmacology and therapeutics

Published: February 13, 2025

Neural effects of dopaminergic compounds revealed by multi-site electrophysiology and interpretable machine-learning.

Neural effects of dopaminergic compounds revealed by multi-site electrophysiology and interpretable machine-learning.

Journal: Frontiers in pharmacology

Published: April 05, 2024

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.

Journal: British journal of clinical pharmacology

Published: January 09, 2024

Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia.

Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia.

Journal: Biological psychiatry

Published: October 04, 2023

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.

Journal: European archives of psychiatry and clinical neuroscience

Published: November 28, 2022

Reply to the Letter to the Editor regarding; Not mismatch negativity modulation of sensory N1 is measured.

Reply to the Letter to the Editor regarding; Not mismatch negativity modulation of sensory N1 is measured.

Journal: Neuroscience

Published: November 11, 2022

Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.

Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents.

Journal: European journal of pharmacology

Published: July 31, 2022

Effects of the mGlu2/3 receptor agonist LY379268 on two models of disturbed auditory evoked brain oscillations in mice.

Effects of the mGlu2/3 receptor agonist LY379268 on two models of disturbed auditory evoked brain oscillations in mice.

Journal: Translational psychiatry

Published: April 14, 2022

Increasing the Excitatory Drive Rescues Excitatory/Inhibitory Imbalance and Mismatch Negativity Deficit Caused by Parvalbumin Specific GluA1 Deletion.

Increasing the Excitatory Drive Rescues Excitatory/Inhibitory Imbalance and Mismatch Negativity Deficit Caused by Parvalbumin Specific GluA1 Deletion.

Journal: Neuroscience

Published: January 28, 2022

Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia.

Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia.

Journal: The Journal of pharmacology and experimental therapeutics

Published: December 22, 2021

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809).

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809).

Journal: Translational psychiatry

Published: December 07, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026